From:
Discussion_Group : Leads on Marketing and Business Development Positions
Date: 6/14/98
Time: 4:14:51 PM
Remote User:
There are very few international Biotech sites. You can check out http://www.biotactics.com/internation.htm for the ones we have heard of. If you find out about others please send us an email and we'll post them.
BioTactics Webmaster
From: AlphaRx
Discussion_Group : Best Biotech Sites on the Web for Marketing/Business
Date: 3/26/2002
Time: 10:01:00 AM
Remote User:
AlphaRx Announces Letter of Intent To Acquire Pharmaceutical Manufacturing Company
RICHMOND HILL, Ontario, Mar 26, 2002 (BW HealthWire) -- AlphaRx Inc. (OTCBB: ALRX) announced today that it has signed a letter of intent to acquire all the stock of a privately held US pharmaceutical manufacturing company. The Company manufactures under contract and private label business, with over 200 vitamin and mineral supplements in its product line. Financials details of the proposed acquisition are not disclosed at this time. Deloitte and Touche Corporate Finance Canada Inc. will be advising the Company on the acquisition. The acquisition is expected to close in April of 2002.
"This acquisition supports AlphaRx's strategy on focusing on revenue growth, profit generation and operational improvements. It expedites the commercialization of our drug delivery technologies in the US as well as opening new business opportunities internationally. Opportunities for value creation are significant and the acquisition will immediately enhance underlying earnings," said Mr. Michael Lee, President of AlphaRx.
"Our goal is to expand through strategic acquisitions. We believe this is the fastest way to introduce our drug delivery products to the worldwide market place. We are actively pursuing acquisition opportunities that will complement or extend our existing product lines or that would be compatible with our business philosophy and strategic goals. We believe that our leading medical and pharmaceutical research background and innovative product lines provide us with a strategic advantage in pursuing and consummating such opportunities," concluded Mr. Lee.
The acquisition is subject to certain closing conditions, including satisfactory completion of due diligence and execution of the Definitive Agreement.
About AlphaRx
AlphaRx is engaged in the development of novel formulations of drugs that are insoluble or poorly soluble in water. AlphaRx's broad product pipeline consists of carefully selected, currently marketed drugs which, through the application of its proprietary BCD drug delivery technology, offer improved medical benefits over existing products with a strong commercial potential.
FORWARD LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
CONTACT: AlphaRx
Michael M. Lee, 905/762-0745 x 101
or
Econ Investor Relations
Connie Linder, Toll free: 888/368-8705
clinder@investorideas.com
Navigation for No Frames view only:
 |
 |
 |
 |
| | Contents | | Search | | Post | | Home | |
